Human Investing LLC Decreases Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Human Investing LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 2.2% during the fourth quarter, HoldingsChannel reports. The firm owned 13,425 shares of the company’s stock after selling 297 shares during the period. AbbVie comprises about 0.4% of Human Investing LLC’s investment portfolio, making the stock its 26th biggest holding. Human Investing LLC’s holdings in AbbVie were worth $2,386,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also bought and sold shares of the company. Rational Advisors LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $562,000. AlphaCentric Advisors LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $2,313,000. Nicholas Hoffman & Company LLC. raised its position in shares of AbbVie by 3.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 7,881 shares of the company’s stock valued at $1,400,000 after buying an additional 250 shares during the period. Americana Partners LLC raised its position in shares of AbbVie by 270.0% during the 4th quarter. Americana Partners LLC now owns 272,219 shares of the company’s stock valued at $48,373,000 after buying an additional 198,647 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $148,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $193.00 on Monday. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The company has a 50-day moving average of $178.93 and a 200-day moving average of $186.03. The firm has a market cap of $341.05 billion, a price-to-earnings ratio of 80.42, a price-to-earnings-growth ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the previous year, the company earned $2.79 earnings per share. Analysts forecast that AbbVie Inc. will post 12.32 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date is Tuesday, April 15th. AbbVie’s payout ratio is 273.33%.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.25% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently commented on ABBV shares. Argus raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. Bank of America reiterated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Piper Sandler lifted their target price on shares of AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.